Indeed, oncogene addicted NSCLC patients such as those carrying EGFR alterations are shown to be resistant to anti-PD-1/PD-L1 mAbs [76] although there is also data suggesting that activating EGFR mutations led to PD-L1 upregulation in NSCLC as well as animal models showing increase survival after PD-1 therapy in EGFR driven adenocarcinoma [77–80]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.